PATIENT INFORMATION LEAFLET
QuetiapinaMABO 50 mg prolonged-release tablets EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Quetiapina MABO contains a substance called quetiapine. It belongs to a group of medicines called antipsychotics. Quetiapina MABO can be used to treat several diseases, such as:
When usingQuetiapina MABO prolonged-release tabletsto treat major depressive episodes in major depressive disorder, this will be taken in addition to another medicine that is being used to treat this disease.
Your doctor may continue prescribing youQuetiapina MABOeven when you are feeling better.
Do not take Quetiapina MABOif the above applies to you. If you are unsure, consult your doctor or pharmacist before taking Quetiapina MABO.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Quetiapina MABO, if:
Inform your doctor immediately if after taking Quetiapina MABO you experience any of the following:
A combination of fever, intense muscle stiffness, sweating, or a decrease in consciousness (a condition known as "neuroleptic malignant syndrome"). You may need immediate medical treatment.
These conditions may be caused by this type of medication.
Inform your doctor as soon as possible if you have:
Thoughts of suicide and worsening of depression
If you are depressed, you may sometimes think about harming yourself or committing suicide. This may increase when you first start treatment, as all these medications take time to work, usually around two weeks but sometimes longer. These thoughts may also increase if you stop taking your medication abruptly. You may be more likely to think this way if you are a young adult. Information from clinical trials has shown an increased risk of thoughts of suicide and/or suicidal behavior in young adults under 25 with depression.
If you ever think about harming yourself or committing suicide, contact your doctor or go to the hospital immediately. It may help to tell a close family member or friend that you are depressed, and ask them to read this leaflet. You may ask them to tell you if they think your depression is getting worse, or if they are concerned about changes in your behavior.
Weight gain
Weight gain has been observed in patients taking quetiapine. You and your doctor should monitor your weight regularly.
Children and adolescents
Quetiapine MABO should not be used in children and adolescents under 18 years of age.
Other medications and Quetiapina MABO
Inform your doctor if you are taking, have taken recently, or may need to take any other medication.
Do not take Quetiapina MABO if you are using any of the following medications:
Inform your doctor if you areusing any of the following medications:
Before stopping any of your medications, consult your doctor first.
Quetiapina MABO tablets with food, drinks, and alcohol
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant,consult your doctor before using this medication. Do not take Quetiapina MABO during pregnancy, unless your doctor has advised you to. Do not useQuetiapina MABO if you are breastfeeding.
The following symptoms, which may represent withdrawal syndrome, may appear in newborn babies of mothers who have used quetiapine in the last trimester (last three months of pregnancy): tremor, muscle stiffness, and/or weakness, drowsiness, agitation, respiratory problems, and difficulty feeding. If your newborn develops any of these symptoms, you may need to contact your doctor.
Driving and operating machinery
These medications may make you feel drowsy. Do not drive or operate tools or machinery until you know how the tablets affect you.
Effect on Urine Drug Detection Tests
If you are having a urine drug detection test, takingquetiapine may produce positive results for methadone or certain antidepressant medications known as tricyclic antidepressants (TCAs) when using certain analysis methods, although you may not be taking methadone or TCAs. If this occurs, a more specific test may be performed.
Quetiapina MABO contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Liver problems
If you have liver problems, your doctor may change your dose.
Use in elderly patients
If you are an elderly patient, your doctor may change your dose.
Use in children and adolescents
Quetiapina MABO should not be used in children and adolescents under 18 years of age.
If you take more Quetiapina MABO than you should
If you take more Quetiapina MABO than your doctor prescribed, you may feel drowsy, feel dizzy, and experience abnormal heartbeats. Contact your doctor or the nearest hospital immediately. Bring your Quetiapina MABO tablets with you.
You can also call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount taken.
If you forgot to take Quetiapina MABO
If you forget to take a dose, take it as soon as you remember. If it is almost time to take the next dose, wait until then. Do not take a double dose to make up for the missed dose.
If you interrupt the treatment with Quetiapina MABO
If you stop taking Quetiapina MABO abruptly, you may be unable to sleep (insomnia), or you may feel nausea, or you may experience headaches, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest reducing the dose gradually before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Side effects not known (frequency cannot be estimated from available data):
The class of medicines to which Quetiapine MABO belongs may cause heart rhythm problems that can be serious and, in severe cases, fatal.
Some side effects are only observed when a blood test is performed. These include changes in the amount of certain fats (triglycerides and total cholesterol) or blood sugar, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decreases in the number of red blood cells, increased creatine phosphokinase in the blood (a substance found in muscles), decreases in the amount of sodium in the blood, and increases in the amount of prolactin hormone in the blood. Increases in prolactin hormone may, in rare cases, lead to:
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store in the original packaging to protect it from moisture.
This medication does not require any special storage temperature.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Quetiapina MABO prolonged-release tablets
Appearance of Quetiapina MABO prolonged-release tablets and content of the container
The tablets are brown, oblong, biconvex, film-coated, and have “Q 50” engraved on one face.
They are presented in aluminum/PVC/PVDC blisters, in containers of 60 tablets.
Marketing authorization holder
MABO-FARMA, S.A.
Calle Vía de los Poblados, 3, Edificio 6
28033 Madrid,
Spain.
Responsible for manufacturing
Merckle GmbH
Ludwig-Merckle Strasse 3
D-89143 Blaubeuren-Weiler
Germany
or
Teva UK
Brampton Road, HampdenPark, Eastbourne, East Sussex, BN22 9AG
United Kingdom
Last review date of the leaflet: June 2024
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.